EGFR and lung adenocarcinoma: The Iressa Pan-Asia Study (IPASS) trial [36] was the first randomized clinical trial to compare EGFR-TKI with chemotherapy in patients affected by lung adenocarcinoma who were former light smokers or nonsmokers.